Abstract |
A multicenter retrospective study was performed to determine the significance of adding cytarabine (CA) or thiotepa (TT) in the context of total body irradiation (TBI) and cyclophosphamide (CY). A total of 322 patients who underwent allogeneic hematopoietic cell transplantation (HCT) were distributed to the following three groups: TBI/CY (n = 75), TBI/CY/CA (n = 77), and TBI/CY/TT (n = 170). In the TBI/CY/TT group, 164 of patients (96 %) received HCT during the previous year (2000-2005). Multivariate analysis revealed that the TBI/CY/TT group demonstrated a trend of poorer survival rate than the TBI/CY group, [hazard ratio (HR) = 1.49, 95 % confidence interval (CI) 0.99-2.24, P = 0.055] with a higher non-relapse mortality (NRM) (HR = 2.34, 95 % CI 1.35-4.06, P = 0.002) rates, while TBI/CY/CA group demonstrated similar outcomes. Even in the subgroup analyses of disease type or disease risk, the outcomes with intensified conditioning regimens were not superior to those with TBI/CY. In conclusion, although the significant bias has to be carefully considered, the clinical benefit of adding CA or TT to the TBI/CY regimen was not demonstrated.
|
Authors | Takayoshi Tachibana, Masatsugu Tanaka, Maki Hagihara, Rika Kawasaki, Etsuko Yamazaki, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori |
Journal | International journal of hematology
(Int J Hematol)
Vol. 102
Issue 4
Pg. 451-9
(Oct 2015)
ISSN: 1865-3774 [Electronic] Japan |
PMID | 26173594
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytarabine
- Cyclophosphamide
- Thiotepa
|
Topics |
- Adolescent
- Adult
- Allografts
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Chemoradiotherapy
- Cyclophosphamide
(administration & dosage)
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
(mortality, therapy)
- Male
- Metabolic Clearance Rate
- Middle Aged
- Retrospective Studies
- Survival Rate
- Thiotepa
(administration & dosage)
|